

Please type a plus sign (+) inside this box ?



12/19/01

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. Department of Commerce

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substituted for form 1449/PTO INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (use as many sheets as necessary)				Complete If Known													
Sheet <u>1</u> of <u>1</u>		<table border="1" style="width:100%; border-collapse: collapse;"> <tr> <td style="width:50%;">Application Number</td> <td style="width:50%;">Unassigned</td> </tr> <tr> <td>Filing Date</td> <td>Herewith</td> </tr> <tr> <td>First Named Inventor</td> <td>HE et al.</td> </tr> <tr> <td>Group Art Unit</td> <td>Unassigned</td> </tr> <tr> <td>Examiner Name</td> <td>Unassigned</td> </tr> <tr> <td>Attorney Docket Number</td> <td>PF150D2</td> </tr> </table>				Application Number	Unassigned	Filing Date	Herewith	First Named Inventor	HE et al.	Group Art Unit	Unassigned	Examiner Name	Unassigned	Attorney Docket Number	PF150D2
Application Number	Unassigned																
Filing Date	Herewith																
First Named Inventor	HE et al.																
Group Art Unit	Unassigned																
Examiner Name	Unassigned																
Attorney Docket Number	PF150D2																
U.S. PATENT DOCUMENTS																	
Examiner Initials	Cite No. ¹	U.S. Patent Document Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear												
✓	AA	4,800,159	CETUS CORP.	01-24-89													
↓	AB	5,420,245	BOARD OF REGENTS, THE UNIV. OF TEXAS	05-30-95													
OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS																	
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.															
✓	AC	RIEGMAN et al., "Molecular Cloning and Characterization of Novel Prostate Antigen cDNA's," <i>Biochem. and Biophys. Res. Comm.</i> , 155(1):181-188 (August 30, 1988)															
	AD	ISRAELI et al., "Molecular Cloning of a Complementary DNA Encoding a Prostate-specific Membrane Antigen," <i>Cancer Research</i> , 53:227-230 (January 15, 1993)															
	AE	ISRAELI et al., "Sensitive Nested Reverse Transcription Polymerase Chain Reaction Detection of Circulating Prostatic Tumor Cells: Comparison of Prostate-specific Membrane Antigen and Prostate-specific Antigen-based Assays," <i>Cancer Research</i> , 54:6306-6310 (December 15, 1994)															
	AF	DEGUCHI et al., "Detection of Micrometastatic Prostate Cancer Cells in Lymph Nodes by Reverse Transcriptase-Polymerase Chain Reaction," <i>Cancer Research</i> , 53:5350-5354 (November 15, 1993)															
	AG	MATOBA et al., "The addition of 5'-coding information to a 3'-directed cDNA library improves analysis of gene expression," <i>Gene</i> , 146:199-270 (September 1994)															
	AH	GenBank Accession No. D17020, MATOBA et al., "Human HepG2 partial cDNA, clone hmd3a07m5" (December 1, 1994)															
	AI	LEWIN, "Genes V" (Oxford University Press), page 648 (1994)															
	AJ	NIERMAN et al., "ATCC/NIH Repository Catalogue of Human and Mouse DNA Probes and Libraries, 1-58 (1994)															
	AK	MORENO et al., "Detection of Hematogenous Micrometastasis in Patients with Prostate Cancer," <i>Cancer Research</i> , 52:6110-6112 (1992)															
	AL	KLEINSMITH et al., Textbook 2nd Ed. "Principles of Cell and Molecular Biology," (ISBN 0-06 5004 04-3, page 528 (1995 2nd)															
	AM	GenBank Accession No. R20331; HILLIER et al. (April 17, 1995)															
	AN	GenBank Accession No. R12745, HILLIER et al. (April 12, 1995)															
	AO	THIGPEN et al., "Molecular Genetics of Steroid 5α-Reductase 2 Deficiency," <i>J. Clinical Invest.</i> , 90:799-809 (September 1992)															
	AP	AKALU et al., "Somatic Mutations at the SRD5A2 Locus Encoding Prostatic Steroid 5α-Reductase During Prostate Cancer Progression," <i>J. Urology</i> , 161:1355-1358 (April 1999)															
	AQ	Supplementary Partial European Search Report, Application No. EP95911712 (August 3, 2000)															
✓	AR	LIN et al., "Prostate Short-Chain Dehydrogenase Reductase 1 (PSDR1): A New Member of the Short-Chain Steroid Dehydrogenase/Reductase Family Highly Expressed in Normal and Neoplastic Prostate Epithelium," <i>Cancer Research</i> , 61:1611-1618 (February 15, 2001)															
Examiner		M. T. DAVIS		Date Considered 10/20/04													

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIP Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.